MiniMed Group, Inc. revenue by segment MMED

MiniMed Group, Inc. splits its revenue into 4 lines in its filings. The largest line in Q1 of fiscal 2027, the quarter ended Jul 31, 2026 was Continuous Glucose Monitoring Systems CGM at $431.0 million, 51% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jul 31, 2026
Q1 FY2027
Jul 31, 2026
Q4 FY2026
Apr 24, 2026
Q3 FY2026
Jan 23, 2026
Revenue
—
843
837
790
Continuous Glucose Monitoring Systems CGM
—
431
share 51.1%
420
share 50.2%
390
share 49.4%
Consumables
—
261
share 31.0%
249
share 29.7%
244
share 30.9%
Pumps
—
144
share 17.1%
145
share 17.3%
151
share 19.1%
Product And Service Other
—
7
share 0.8%
22
share 2.6%
5
share 0.6%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
MMED (Nasdaq), MMEDV (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Northridge, CA
SEC filer status
Non-accelerated filer
SEC CIK
2062583
Former names
MDT Sub Holdings, Inc. (until May 30, 2025)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.